Seattle's Nohla closes $45M to bring novel stem cell treatment for leukemia to late-stage trials
Seattle’s Nohla Therapeutics, a biotech startup spun out of the Fred Hutchinson Cancer Research Center, has raised $45 million in new money to push forward its Phase II cell therapy for cord blood transplants.
The new Series B, backed in part by Celgene $CELG and Fidelity, brings the company’s total haul to $88.5 million since Nohla’s 2015 launch.
The company is developing a cellular technology platform first invented by the company’s co-founder and CMO Colleen Delaney. First up, the startup is tackling a novel stem cell treatment for leukemia that uses cells from donated umbilical cord blood. It could be more effective than traditional bone marrow transplants.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.